ANGIEX INC has a total of 11 patent applications. Its first patent ever was published in 2018. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are ARCELLX INC, NKARTA INC and DEMETER BIOTECH LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 3 | |
#2 | Australia | 2 | |
#3 | Canada | 2 | |
#4 | EPO (European Patent Office) | 2 | |
#5 | China | 1 | |
#6 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Climate change adaptation technologies | |
#5 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Jaminet Paul A | 10 |
#2 | Jaminet Shou-Ching S | 10 |
#3 | Presta Leonard G | 6 |
#4 | Dvorak Harold F | 6 |
#5 | Ha Edward | 5 |
#6 | Jaminet Shou-Ching | 1 |
#7 | Presta Leonard | 1 |
#8 | Jaminet Paul | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020176794A1 | Antibody-drug conjugates comprising anti-tm4sf1 antibodies and methods of using the same | |
AU2019284915A1 | Antibody-oligonucleotide conjugates | |
CN111565750A | anti-TM 4SF1 antibodies and methods of use thereof |